Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Saxon, it looks as though Priaxon has been inactive for the past six years.
Monkshood, currently 7% of my pension is in this share so I clearly believe in the product. But I no longer take the AN/company forecasts seriously; just let it roll. Lockdown started on 23rd March, 7 working days before FDA submission date and they had not finished drawing blood samples let alone testing them , doing the analysis, writing up the report and eventually finalising the submission. And all because of the lockdown. I think (hope) the technology is a winner and will be approved but don't even bother reading most RNS publications now. I will learn the results one day from the share price. Good luck.
Sharesting or anyone, Richard Griffiths, the largest private investor recently sold all his shares. Now the largest institutional investor is thought to be strenuously selling shares.... Question for the next pub quiz - why do professional investors sell off shares with the best prospects when they need cash? Why not just dump the ones with no prospects medium term?
Manifesto, thanks. Just turned off the Monday morning RNS alarm. At least I'll be able to sleep a bit longer :-)
Saxon, if Faron is making the Oxford vaccine they might not be making losses again. Ever. I don't understand the biochemistry but have to trust the posters here.
CB, alarm set for 6.55! Hope the wife doesn't get too grumpy......
CB, fantastic news must be an understatement. As the trial has been launched and first patients next week should Faron be notifying by RNS 7 am Monday? The company must realise it is price sensitive. Or do you think they will try to keep schtum for some reason?
Oscar, the clap of doom you might be hearing is in fact the cavalry of partners galloping to our rescue. Good luck.
Thanks Tiptree.
The earlier Recovery trial protocol, dated 4th April shows Interferon as one of the treatment arms. " Arm 3: Interferon-?-1a. Nebulized solution of IFN-ß1a 6MIU (0.5ml of a solution
containing 12MIU/ml) once-daily for 10 days or until discharge. "
This is the treatment arm which has been dropped in favour of Azithromycin in the current protocol.
As the original interferon beta was nebulized, I assumed it was the Synairgen product. I also have shares in Faron which supplies injectable Interferon used in the REMAP-CAP trial.
SG, Recovery trial webpage states that Interferon has been dropped
Item 2 on update states:
"Adding azithromycin as an arm to the trial (replacing interferon beta)"
I assume that is not good news but very happy to be proved wrong.
Could the late reported 25k sale at 10.13 have been a buy? Sale prices then were around 433p so big sale should have been lower, not higher at 439. Or am I just whistling in the dark?